Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
74 suicide warnings and 243 mentions of hanging: What ChatGPT said to a suicidal teen - 2At least 7 dead as Israel renews attacks on Beirut and across Lebanon
- 3Germany unveils rescue plan for struggling chemical sector
- 4Figure out How to Analyze Medical attendant Compensation Patterns Across Different Specializations
- 5Misjudged Objections For Solo Voyagers
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
- How a cocktail of rogue storms and climate chaos unleashed deadly flooding across Asia
- Man Charged for Stealing ‘Incredibly Precious’ 286-Year-Old Violin, Worth More Than $200,000, from a Tavern
- 2025 Was Another Exceptionally Hot Year
- A Colombian city swaps iconic horse buggies for electric carriages amid animal welfare concerns
- Defense Minister Katz finally condemns Jewish extremist violence against Palestinians
- Two Passover initiatives target isolation and safety for Israel’s elderly
- Carnival fever hits Lagos as locals celebrate Afro-Brazilian heritage
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
